

Notification of Expiry of Listed Options

3 September 2025

Melbourne, Australia, 3 September 2025 – 4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company"), a global leader in respiratory imaging technology, advises that the attached letter has been sent to registered holders of listed options (ASX:4DXOA) (**Listed Options**) which are exercisable at \$0.55 on or before 5pm (AEST) on 1 October 2025 (**Expiry Date**).

Official quotation of the Listed Options on ASX will cease at close of trading on 25 September 2025, being four business days before the Expiry Date.

Holders of the Listed Options can exercise all or part of their Listed Options prior to the Expiry Date by either:

- Completing a personalised "Notice of Exercise of Options" form (Notice of Exercise)
 accompanying the letter and provide the completed Notice of Exercise together with
 payment in cleared funds of \$0.55 per Listed Option being exercised in accordance with the
 instruction set out in the Notice of Exercise, OR:
- Complete an application and remit funds via the Offer Website, at: https://events.miraqle.com/4dx-offer/

Further instructions are provided in the attached letter.

-ENDS-

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate	Administration	Media Enquiries
Investor Relations	Company Secretary	4Dmedia@4dmedical.com
investor.relations@4dmedical.com	companysecretary@4dmedical.com	

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), CT LVAS™, and the ground-breaking CT:VQ™ solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient



care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com



03 September 2025

Dear Option Holder

UPCOMING EXPIRY OF 4DMEDICAL OPTIONS (ASX:4DXOA)

We are writing to you as a registered holder of listed 4DMedical Limited (ASX:4DX) (**4DMedical**) options (**Listed Options**).

As you know, the Listed Options expire on the earlier of 28 February 2026 and the date being 30 days from the date of 4DMedical's announcement of receipt of clearance from the U.S. Food and Drug Administration (**FDA**) for its ventilation and perfusion technology, CT:VQ[™]. As announced to market on 1 September 2025, 4DMedical successfully obtained FDA clearance for its CT:VQ[™] technology. As a result, in accordance with the terms of the Listed Options, the expiry date of the Listed Options is 1 October 2025 (**Expiry Date**).

We are therefore writing to remind you that the Listed Options you hold will expire at 5:00pm (AEST) on the Expiry Date. Details of how to exercise your Listed Options (at the exercise price of \$0.55 (55 cents) per Listed Option) into fully paid ordinary shares in 4DMedical are set out below.

There is no obligation for option holders to exercise some or all of their Listed Options. The courses of actions available to you as a holder of these soon-to-expire Listed Options are to:

- a) **Exercise your Listed Options:** Should you wish to exercise some or all of your Listed Options, you must either:
 - Complete your personalised "Notice of Exercise of Options" form (Notice of Exercise)
 accompanying this letter and provide the completed Notice of Exercise together with payment
 in cleared funds of \$0.55 per Listed Option being exercised in accordance with the instruction
 set out in the Notice of Exercise, OR:
 - Complete your application and remit funds via the Offer Website, at: https://events.miragle.com/4dx-offer/

Your completed Notice of Exercise or application via the Offer Website, and payment (in cleared funds), must be received by no later than 5:00pm (AEST) on the Expiry Date, failing which the Listed Options will automatically lapse. Instructions regarding methods of payment are included in the Notice of Exercise and also outlined on the Offer Website. Should you exercise your Listed Options and be issued 4DMedical shares at \$0.55 per share, you will automatically be granted an additional option in 4DMedical (**Piggyback Option**). Piggyback Options are exercisable at \$0.75 with an expiry date 1 September 2027.

While 4DMedical intends to apply for quotation of the Piggyback Options on the ASX, quotation is dependent on the satisfaction of, among other things, ASX Listing Rule 2.5, condition 6, which requires that there are at least 100,000 Piggyback Options on issue and at least 50 holders of a marketable parcel of Piggyback Options. As at the date of this notice, 4DMedical cannot guarantee that the conditions for quotation of the Piggyback Options will be satisfied. If the conditions for quotation are not satisfied, the Piggyback Options will continue to be issued but will not be quoted on the ASX.



- b) **Sell your Listed Options:** Please note that official quotation of the Listed Options on the Australian Securities Exchange (**ASX**) will <u>cease at close of trading on 25 September 2025</u>, being four business days before the Expiry Date. Listed Options will not be able to be traded on the ASX after this time.
- c) **Do nothing and allow your Listed Options to expire:** If you do not exercise or sell your Listed Options in the manner described above, the Listed Options will automatically <u>expire at 5:00pm (AEST) on the Expiry Date</u> and your right to exercise the Listed Options and be issued 4DMedical shares will automatically lapse. Should you allow your Listed Options to expire, you will not be granted additional Piggyback Options as described above.

Notice of Exercise

Your Notice of Exercise can also be requested directly from the share registry. Please contact MUFG Corporate Markets on:

- Telephone (within Australia): 1300 554 474
- Telephone (outside Australia): +61 300 554 474
- Email: support@cm.mpms.mufg.com

Additionally, to check your existing holdings, you may log in to the MUFG Investor Centre via the following link: Login - MUFG Investor Services

In accordance with clause 5.2 of Appendix 6A of the ASX Listing Rules, 4DMedical provides the following information:

- a) the name of the holder of the Listed Options, the number of Listed Options held and the number of shares to be issued on exercise of the Listed Options is set out in the personalised Notice of Exercise accompanying this letter;
- b) the exercise price of the Listed Options is \$0.55 per Listed Option;
- c) the Listed Options must be exercised and payment (in cleared funds) received by no later than 5:00pm (AEST) on 1 October 2025 (being the Expiry Date);
- d) if you do not exercise your Listed Options in the manner described above, they will automatically expire at 5:00pm (AEST) on the Expiry Date and your right to exercise your Listed Options and be issued 4DMedical shares at \$0.55 per share will automatically lapse;
- e) official quotation of the Listed Options on the ASX will cease at close of trading on 25 September 2025, being four business days before the Expiry Date;
- f) the market price of 4DMedical shares on the ASX on 2 September 2025 was \$0.770, being the closing price of shares on the ASX;
- g) during the 3 months preceding 2 September 2025:
 - i. the highest market sale price of 4DMedical shares on the ASX was \$0.855 on 2 September 2025; and
 - ii. the lowest market sale price of 4DMedical shares on the ASX was \$0.23 on 9 July 2025.
- h) as at the date of this notice, there are no underwriting agreements in relation to the Listed Options.

If you have any questions regarding the exercise of your Listed Options or need assistance with accessing your Holding Number, please contact MUFG Corporate Markets on:

- Telephone (within Australia): 1300 554 474



- Telephone (outside Australia): +61 300 554 474
- Email: support@cm.mpms.mufg.com

Yours sincerely,

Dr Andreas Fouras

Founder and CEO



ACN 161 684 831

All Registry communications to: MUFG Corporate Markets (AU) Limited A division of MUFG Pension & Market Services

Locked Bag A14

Sydney South NSW 1235 Australia

Telephone: 1300 554 474

From outside Australia: +61 1300 554 474 ASX Code: 4DXOA

Email: capital.markets.au@cm.mpms.mufg.com Website: au.investorcentre.mpms.mufg.com

IID:

SRN/HIN:

Conversion Ratio: 1 Option for 1 Ordinary Share

and 1 Piggyback Option

Exercise Price: \$0.55

4DXOA held as at 1 September 2025:

Expiry date: 1 October 2025

NOTICE OF EXERCISE OF OPTIONS

PLEASE COMPLETE BELOW (using block letters) - refer overleaf for details and further instructions on how to complete this form.

I/We apply to exercise the following number of options and make payment in Australian currency for the amount payable. Please allot me/ us Ordinary Shares and Piggyback Options calculated on the basis of one (1) Ordinary Share and one (1) Piggyback Option for every one (1) Option which I/we exercise. I/We agree to accept such Shares and Piggyback Options subject to the Constitution of 4DMedical Limited.

Α	NUMBER OF OPTIONS EXERCISED (Exercise all or part of 4DXOA Options)	
7.	(Exercise all or part of 4DXOA Options)	
		at \$0

B TOTAL PAYMENT REQUIRED (\$0.55 per 4DXOA Option exercised)

at \$0.55 per
Option Exercised A\$

PAYMENT OPTIONS

Option 1: Paying by BPAY®

If paying by BPAY®, refer to the instructions overleaf. You do NOT need to return this form if you elect to make payment by BPAY®. Payment must be received via BPAY® before the expiry date of the options. You should check the processing cut off-time for BPAY® transactions with your bank, credit union or building society to ensure your payment will be received by the Registry in time. By paying by BPAY® you will be deemed to have completed a Notice of Exercise of Options for the number of Shares and Piggyback Options the subject of your payment.



Biller Code: 445791

Ref:

Option 2: Paying by Bank Transfer

If you are unable to make payment via BPAY®, please contact MUFG Corporate Markets at capital.markets.au@cm.mpms.mufg.com to obtain the relevant banking details.

When paying via bank transfer please ensure that your SRN/HIN is used as your reference number. Failure to use this will result in your payment being unable to be matched and therefore it will not be processed.

Telephone & Internet Banking – BPAY®

Contact your bank or financial institution to make this payment from your cheque, savings, debit or transaction account. More info: www.bpay.com.au ® Registered to BPAY Pty Ltd ABN 69 079 137 518



HOW TO COMPLETE THE NOTICE OF EXERCISE OF OPTIONS

Please complete all relevant sections of this form USING BLOCK LETTERS. These instructions are cross referenced to each section of the notice.

A. Application for Shares and Piggyback Options under the Notice of Exercise of Options

You may exercise either part of, or all of, your Options holding. Please write in Box A the number of Options that you wish to exercise.

If you do not indicate the number of Options you wish to Exercise, the Company will exercise as many Options as your accompanying payment will pay for. The number of Options exercised, however, will not exceed the number of Options that you hold.

B. Total Payment Required for Options Exercise

Please enter in Box B the total amount of the payment required for the Options you wish to exercise at the Exercise Price of \$0.55 per Option.

C. Payment Details

Using the BPAY® Payments details on the overleaf, make payment directly using BPAY®.

If you are unable to make payment via BPAY®, please contact MUFG Corporate Markets at capital.markets.au@cm.mpms.mufg.com to obtain the relevant banking details.

Consequence of non-payment

If a Notice of Exercise and the required payment are not received before the expiry date, the Options will automatically expire and no longer be available for exercise.

If you require information on how to complete this form please contact the MUFG Corporate Markets Information Line on 1300 554 474 if calling within Australia or +61 1300 554 474 if calling from outside of Australia, between 8:30am and 5:00pm (AEST) Monday to Friday.

If you are unsure as to whether or not to exercise your Options, please consult your investment, financial, taxation or other professional adviser.

